Biotech, Patents, Ariad

Ariad Persuades Court to Allow Immediate Appeal of Ruling in Favor of Amgen

Luke Timmerman 10/6/08

Ariad Pharmaceuticals, the Cambridge, MA-based biotech company, said today that the U.S. District Court in Delaware has allowed an immediate appeal of a ruling that said Amgen’s arthritis drug Enbrel isn’t infringing on Ariad’s patents. A ruling on the appeal is expected to take 12 to 18 months, said Ariad CEO Harvey Berger, in a statement.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.